Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine

This study has been terminated.
(For various reasons.)
Sponsor:
Information provided by (Responsible Party):
James C. Patterson, II, MD. Ph, Louisiana State University Health Sciences Center Shreveport
ClinicalTrials.gov Identifier:
NCT00595582
First received: January 4, 2008
Last updated: May 25, 2012
Last verified: May 2012
  Purpose

This is an additional study to the primary Mild Cognitive Impairment (MCI) study (LSU#H04-049; NCT00243451)that is underway of PET detection of Mild Cognitive Impairment. This study has preliminary data that indicates objective analysis of PET brain image metabolic data is a sensitive marker for AD. The goal of this proposal is to determine the efficacy of curcumin in the treatment of MCI or mild Alzheimer's Disease (AD).


Condition Intervention
Mild Cognitive Impairment
Dietary Supplement: curcumin + bioperine

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine

Resource links provided by NLM:


Further study details as provided by Louisiana State University Health Sciences Center Shreveport:

Primary Outcome Measures:
  • Neuropsychological Scores in Patients With MCI or Mild AD. [ Time Frame: within the next three years ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: May 2005
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
single arm
Curcumin + Bioperine
Dietary Supplement: curcumin + bioperine
Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
Other Name: Life Extension Super Bio-Curcumin

Detailed Description:

The specific aims of this study include:

  • Determine if curcumin has an effect on neuropsychological scores in patients with MCI. Working Hypothesis: Patients with MCI that have evidence of objective memory impairment will have improvement on neuropsychological test scores.
  • Determine if curcumin impacts the metabolic lesions found in patients who have MCI or may develop MCI. Working hypothesis: The metabolic lesions present that are consistent with the development of early AD will improve with curcumin treatment.

Patients diagnosed with MCI, patients who have metabolic lesions consistent with premorbid MCI, or mild AD and are currently enrolled in the primary MCI study (LSU#H04-049; NCT00243451) will be invited to participate in this clinical trial.

These subjects will be treated with 5.4 grams of curcumin per day (900 mg pills, two pills 3X/day with meals) with the inclusion of bioperine additive (formulated with the curcumin capsules) to improve bioavailability of the curcumin. Patients will be treated with curcumin/bioperine for 24 months concordant with the last two years of the three year longitudinal primary MCI study. Clinical endpoints will be change in neuropsychological scores, and size of metabolic lesions on the PET scan. Both of these measures will be recorded as part of the primary MCI study.

  Eligibility

Ages Eligible for Study:   55 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

MCI Inclusion Criteria:

MCI criteria met:

  • Memory complaint
  • Objective memory impairment based on test scores
  • Normal general cognitive function.
  • Intact Activities of Daily Living.
  • Not demented.
  • At least 10 years of education, or GED, or equivalent.
  • Patients with ApoE4 positive homozygous or heterozygous status and/or first-degree relative with probable AD are preferred
  • Age: 55-85
  • Have normal or clinically unimportant physical exam,
  • Able to give informed consent, or assent
  • MRI findings must be normal or unremarkable for the age of the patient.

Exclusion Criteria:

  • Other neuropsychiatric diagnoses
  • Major medical illness including potential secondary causes of cognitive decline.
  • Disease, combination of disease, or presentation that, in the clinician's judgment, could introduce intolerable variance into the PET brain scan image
  • Current substance or alcohol dependence or history of same, and no alcohol or substance abuse within the last eight weeks.

Mild Alzheimer's Disease (AD) Inclusion criteria (patients):

  • You must have a Mini Mental State Examination score of greater than 20.
  • You must have one or more of these signs and symptoms of mild AD all of which impair function and are worsening over time:

    1. Cognitive impairment manifested as memory problems
    2. problems with language
    3. difficulty carrying out motor activities
    4. difficulty naming things
    5. problems planning or organizing
  • You must have at least 10 years of education, or a GED, or its equivalent.
  • Positive for the ApoE4 genetic marker through blood test, or meet all other inclusion/exclusion criteria without exception.
  • Age: 55-85.
  • Normal or clinically unimportant physical exam
  • Able to give informed consent/assent
  • If you take medications that have an effect on the brain, they will be closely monitored. You will be PET-scanned only after a 24-hour washout of this medication(s), but this medication(s) will be restarted immediately after the scan.

Mild Alzheimer's Disease (AD) Exclusion Criteria:

  • Any problems related to the brain or mental disorders other than mild AD.
  • You will get an MRI of your brain taken on the second visit, and a radiologist will read it. If there are any abnormal findings, you will be told, and these findings will be forwarded to your medical doctor. These findings may or may not result in your exclusion from the study.
  • Any major medical illness
  • Any disease, combination of disease, or presentation that, in the clinician's judgment, could introduce intolerable variance into the PET brain scan image.
  • Current diagnosis of substance or alcohol dependence or a history of same and no alcohol or substance abuse within the last eight weeks.

MCI Inclusion criteria (controls)

  • Normal cognitive screening exam.
  • Age: 55-85.
  • At least 10 years of education or GED, or equivalent.
  • Socioeconomic status, age, and sex matched.
  • Able to give informed consent, or assent
  • Centrally acting medications will be closely tracked, patients on any such medications will be PET-scanned only after a 24-hour washout, with meds restarted immediately after the scan.

MCI Exclusion criteria (controls)

  • First-degree relative with dementia or clinically relevant memory problems.
  • Other Neuropsychiatric diagnoses
  • Major medical illness
  • Current or history of substance or alcohol dependence; no alcohol or substance abuse within the last eight weeks.
  • MRI findings must be normal or unremarkable for the age of the patient.
  • Disease, combination of disease, or presentation that, in the clinician's judgment, could introduce intolerable variance into the PET brain scan image

Dropout criteria (all):

  • Adverse events intolerable to the patient that prevent continued involvement in the study.
  • New onset medical disorder of such significance as to prohibit further involvement.
  • Initiation or recurrence of alcohol or substance abuse/dependence.
  • Subject withdraws consent for any reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00595582

Locations
United States, Louisiana
Louisiana State University Health Sciences Center
Shreveport, Louisiana, United States, 71103
Sponsors and Collaborators
Louisiana State University Health Sciences Center Shreveport
Investigators
Principal Investigator: James C Patterson, MD, PhD LSU Health Sciences Center
  More Information

No publications provided

Responsible Party: James C. Patterson, II, MD. Ph, Professor, Louisiana State University Health Sciences Center Shreveport
ClinicalTrials.gov Identifier: NCT00595582     History of Changes
Other Study ID Numbers: LSU#H05-168, LSU#H05-168
Study First Received: January 4, 2008
Results First Received: October 11, 2011
Last Updated: May 25, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Cognition Disorders
Mild Cognitive Impairment
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Curcumin
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Central Nervous System Agents

ClinicalTrials.gov processed this record on August 26, 2014